Display Settings:

Format

Send to:

Choose Destination
    J Antibiot (Tokyo). 2011 Jan;64(1):59-64. Epub 2010 Nov 17.

    Improved precursor-directed biosynthesis in E. coli via directed evolution.

    Source

    Department of Chemistry, Stanford University, Stanford, CA 94305-5080, USA.

    Abstract

    Erythromycin and related macrolide antibiotics are widely used polyketide natural products. We have evolved an engineered biosynthetic pathway in Escherichia coli that yields erythromycin analogs from simple synthetic precursors. Multiple rounds of mutagenesis and screening led to the identification of new mutant strains with improved efficiency for precursor-directed biosynthesis. Genetic and biochemical analysis suggested that the phenotypically relevant alterations in these mutant strains were localized exclusively to the host-vector system, and not to the polyketide synthase. We also demonstrate the utility of this improved system through engineered biosynthesis of a novel alkynyl erythromycin derivative with comparable antibacterial activity to its natural counterpart. In addition to reinforcing the power of directed evolution for engineering macrolide biosynthesis, our studies have identified a new lead substance for investigating structure-function relationships in the bacterial ribosome.

    PMID:
    21081955
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3030684
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 2
    Figure 1
    Figure 3

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk